The present invention provides a pharmaceutical composition in the form of a dry powder for inhalation comprising abediterol or a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable carrier, providing upon inhalation a dose equivalent to a metered nominal dose of about 1.25 or about 2.5 micrograms of free base abediterol administered with the GenuairR inhaler. The present invention also provides said pharmaceutical composition for use in the treatment of respiratory disease such as asthma and chronic obstructive pulmonary disease COPD.本發明提供一種用於吸入之乾燥粉末形式之藥學組成物，包含與藥學上可接受載體混合之阿貝特羅(abediterol)或藥學上可接受鹽類，提供吸入劑量相當於以GenuairR吸入器給藥之定量標稱劑量(metered nominal dose)約1.25或約2.5微克的游離鹼阿貝特羅(abediterol)。本發明也提供該藥學組成物使用於治療例如哮喘及慢性阻塞性肺疾病(chronic obstructive pulmonary disease，COPD)之呼吸道疾病。
